These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18379193)

  • 41. Metabolic Volumetric Parameters in
    Tseng JR; Yang LY; Lin YC; Liu CY; Pang ST; Hong JH; Yen TC; Wang LJ
    Contrast Media Mol Imaging; 2018; 2018():8945130. PubMed ID: 30532664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Positron emission tomography (PET) in oncology (Part I)].
    Gámez Cenzano C; Cabrera Villegas A; Sopena Monforte R; García Velloso MJ
    Rev Esp Med Nucl; 2002 Feb; 21(1):41-60; quiz 61-3. PubMed ID: 11821003
    [No Abstract]   [Full Text] [Related]  

  • 43. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PET tracers in musculoskeletal disease beyond FDG.
    Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
    Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET/MRI radiotracer beyond ¹⁸F-FDG.
    Pampaloni MH; Nardo L
    PET Clin; 2014 Jul; 9(3):345-9. PubMed ID: 25030398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Delineation of glioblastoma, simplicity to complexity, the contribution of imaging].
    Noël G; Guillevin R
    Cancer Radiother; 2011 Oct; 15(6-7):484-94. PubMed ID: 21862374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-fluorocholine: a new oncologic PET tracer.
    Hara T
    J Nucl Med; 2001 Dec; 42(12):1815-7. PubMed ID: 11752078
    [No Abstract]   [Full Text] [Related]  

  • 48. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Practice guidelines for PDG-PET cancer screening].
    Japanese Society of Nuclear Medicine
    Kaku Igaku; 2004 Nov; 41(4):1-21. PubMed ID: 15690769
    [No Abstract]   [Full Text] [Related]  

  • 50. Tumor hypoxia: the role of nuclear medicine.
    Cook GJ; Fogelman I
    Eur J Nucl Med; 1998 Apr; 25(4):335-7. PubMed ID: 9643970
    [No Abstract]   [Full Text] [Related]  

  • 51. [Monitorized use of 18FDG positron emission tomography].
    Rodríguez Garrido M; Asensio del Barrio C
    Rev Esp Med Nucl; 2006; 25(3):217-20. PubMed ID: 16871675
    [No Abstract]   [Full Text] [Related]  

  • 52. Synthesis of oncological [11C]radiopharmaceuticals for clinical PET.
    Lodi F; Malizia C; Castellucci P; Cicoria G; Fanti S; Boschi S
    Nucl Med Biol; 2012 May; 39(4):447-60. PubMed ID: 22172394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The DAT ligand [(18)F]PR17.MZ mirrors the in vivo pharmacokinetic profile of [(11)C]cocaine with significantly improved monoamine transporter selectivity.
    Riss PJ; Piel M; Bockhart V; Bausbacher N; Buchholz HG; Lueddens H; Roesch F
    ChemMedChem; 2010 Oct; 5(10):1686-8. PubMed ID: 20830722
    [No Abstract]   [Full Text] [Related]  

  • 54. Proliferation imaging to measure early cancer response to targeted therapy.
    Mankoff DA; Eary JF
    Clin Cancer Res; 2008 Nov; 14(22):7159-60. PubMed ID: 19010830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positron emission tomography (PET) in the evaluation of patients with cancer.
    Godwin HA; Zuger JH
    Trans Am Clin Climatol Assoc; 1999; 110():181-94. PubMed ID: 10344016
    [No Abstract]   [Full Text] [Related]  

  • 56. Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type-1 receptors.
    Ahamed M; Verbruggen A; Bormans G
    J Labelled Comp Radiopharm; 2013; 56(3-4):207-14. PubMed ID: 24285327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reliability and reproducibility of N-[11C]methyl-choline and L-(S-methyl-[11C])methionine solid-phase synthesis: a useful and suitable method in clinical practice.
    Lodi F; Rizzello A; Trespidi S; Di Pierro D; Marengo M; Farsad M; Fanti S; Al-Nahhas A; Rubello D; Boschi S
    Nucl Med Commun; 2008 Aug; 29(8):736-40. PubMed ID: 18753828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and cancer.
    Gao M; Yang Q; Wang M; Miller KD; Sledge GW; Zheng QH
    Appl Radiat Isot; 2013 Apr; 74():61-9. PubMed ID: 23376309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PET radioligands targeting the brain GABAA /benzodiazepine receptor complex.
    Andersson JD; Halldin C
    J Labelled Comp Radiopharm; 2013; 56(3-4):196-206. PubMed ID: 24285326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours.
    Tsouana E; Stoneham S; Fersht N; Kitchen N; Gaze M; Bomanji J; Fraioli F; Hargrave D; Shankar A
    Pediatr Blood Cancer; 2015 Sep; 62(9):1661-3. PubMed ID: 25854508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.